BioTime (BTX)’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel’s Office of the Chief Scientist
5/13/2013 10:07:01 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences) today announced that Cell Cure Neurosciences has been awarded a grant of 5.34 million Shekels, approximately $1.5 million, for 2013 from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product in development by Cell Cure Neurosciences for the treatment of age-related macular degeneration. Cell Cure Neurosciences’ plans for the development of OpRegen® include completion of preclinical testing and filing an application to commence human clinical trials in 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by